PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28404991-5 2017 Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol. Cholesterol 130-141 peroxisome proliferator activator receptor delta Mus musculus 70-79 25662586-1 2015 The peroxisome proliferator-activated receptor (PPAR)-beta/delta has emerged as a promising therapeutic target for treating dyslipidemia, including beneficial effects on HDL cholesterol (HDL-C). Cholesterol 174-185 peroxisome proliferator activator receptor delta Mus musculus 4-58 26683793-10 2016 CONCLUSION: A novel PPARdelta agonist, PYPEP, suppressed atherosclerotic lesion progression by improving the serum lipoprotein profiles, including increased levels of ApoA-I and functional HDL particles, as well as a reduced non-HDL cholesterol level, in hApoB100/hCETP-dTg mice with human-like hypercholesterolemic dyslipidemia. Cholesterol 233-244 peroxisome proliferator activator receptor delta Mus musculus 20-29 25662586-9 2015 Our results also indicate that PPAR-beta/delta activation may modulate PLTP-mediated prebeta-HDL formation and macrophage cholesterol efflux. Cholesterol 122-133 peroxisome proliferator activator receptor delta Mus musculus 31-40 22729460-0 2012 Liver X receptor beta and peroxisome proliferator-activated receptor delta regulate cholesterol transport in murine cholangiocytes. Cholesterol 84-95 peroxisome proliferator activator receptor delta Mus musculus 26-74 22729460-4 2012 Activation of LXRbeta and/or PPARdelta in cholangiocytes induces ATP-binding cassette cholesterol transporter A1 (ABCA1) and increases cholesterol export at the basolateral compartment in polarized cultured cholangiocytes. Cholesterol 86-97 peroxisome proliferator activator receptor delta Mus musculus 29-38 22729460-5 2012 In addition, PPARdelta induces Niemann-Pick C1-like L1 (NPC1L1), which imports cholesterol into cholangiocytes and is expressed on the apical cholangiocyte membrane via specific interaction with a peroxisome proliferator-activated response element (PPRE) within the NPC1L1 promoter. Cholesterol 79-90 peroxisome proliferator activator receptor delta Mus musculus 13-22 20300524-11 2010 Key transcriptional programs activated in psoriasis, including IL1-related signalling and cholesterol biosynthesis, are replicated in the mouse model, suggesting that PPARbeta/delta regulates these transcriptional changes in psoriasis. Cholesterol 90-101 peroxisome proliferator activator receptor delta Mus musculus 167-175 22607770-8 2012 These changes were accompanied by up-regulation of genes involved in cholesterol efflux such as PPARdelta, LXRalpha, and LXRalpha-targeting genes and down-regulation of pro-inflammatory cytokine and chemokine genes in obese TLR3(-/-) mice. Cholesterol 69-80 peroxisome proliferator activator receptor delta Mus musculus 96-105 21426320-4 2011 PPARdelta KI mice displayed a small decrease of high-density lipoprotein-cholesterol whereas other lipid parameters were unaltered. Cholesterol 73-84 peroxisome proliferator activator receptor delta Mus musculus 0-9 20009009-6 2010 Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice. Cholesterol 218-229 peroxisome proliferator activator receptor delta Mus musculus 26-34 20009009-6 2010 Pathways downregulated by PPARbeta/delta deletion included lipoprotein metabolism and various pathways related to glucose utilization, which correlated with elevated plasma glucose and triglycerides and reduced plasma cholesterol in PPARbeta/delta-/- mice. Cholesterol 218-229 peroxisome proliferator activator receptor delta Mus musculus 233-241 20169010-0 2009 Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Cholesterol 105-116 peroxisome proliferator activator receptor delta Mus musculus 9-57 19439761-0 2009 Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux. Cholesterol 95-106 peroxisome proliferator activator receptor delta Mus musculus 0-48 19439761-2 2009 Activation of PPARdelta markedly increases fecal neutral sterol secretion, the last step in reverse cholesterol transport. Cholesterol 100-111 peroxisome proliferator activator receptor delta Mus musculus 14-23 19439761-4 2009 To test the hypothesis that PPARdelta activation leads to stimulation of transintestinal cholesterol efflux (TICE), we quantified it by intestine perfusions in FVB mice treated with PPARdelta agonist GW610742. Cholesterol 89-100 peroxisome proliferator activator receptor delta Mus musculus 28-37 19439761-8 2009 Interestingly, expression of Rab9 and LIMPII, encoding proteins involved in intracellular cholesterol trafficking, was increased upon PPARdelta activation. Cholesterol 90-101 peroxisome proliferator activator receptor delta Mus musculus 134-143 19439761-10 2009 These data show that activation of PPARdelta stimulates fecal cholesterol excretion in mice, primarily by the two-fold increase in TICE, indicating that this pathway provides an interesting target for the development of drugs aiming at the prevention of atherosclerosis. Cholesterol 62-73 peroxisome proliferator activator receptor delta Mus musculus 35-44 20169010-0 2009 Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Cholesterol 186-197 peroxisome proliferator activator receptor delta Mus musculus 9-57 20169010-1 2009 Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT). Cholesterol 83-94 peroxisome proliferator activator receptor delta Mus musculus 0-48 20169010-1 2009 Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT). Cholesterol 83-94 peroxisome proliferator activator receptor delta Mus musculus 50-59 20169010-1 2009 Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT). Cholesterol 168-179 peroxisome proliferator activator receptor delta Mus musculus 0-48 20169010-1 2009 Peroxisome proliferator-activated receptor delta (PPARdelta) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage-to-feces reverse cholesterol transport (RCT). Cholesterol 168-179 peroxisome proliferator activator receptor delta Mus musculus 50-59 20169010-9 2009 In conclusion, PPARdelta activation enhances excretion of macrophage or HDL-derived cholesterol in feces through reduced NPC1L1 expression in mice, comparable to the effect of ezetimibe. Cholesterol 84-95 peroxisome proliferator activator receptor delta Mus musculus 15-24 15604518-8 2005 PPARdelta activation is associated with increased plasma HDL and reduced intestinal cholesterol absorption efficiency that may be related to decreased intestinal Npc1l1 expression. Cholesterol 84-95 peroxisome proliferator activator receptor delta Mus musculus 0-9 16083348-6 2005 PPARbeta/delta activation also prevents the development of obesity and improves cholesterol homeostasis in obesity-prone mouse models. Cholesterol 80-91 peroxisome proliferator activator receptor delta Mus musculus 0-8 19009042-4 2008 The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain. Cholesterol 243-254 peroxisome proliferator activator receptor delta Mus musculus 89-97 19009042-4 2008 The lipid content alteration observed in PPARbeta null brains and the positive action of PPARbeta agonists on oligodendrocyte differentiation, a process characterized by lipid accumulation, suggest that PPARbeta acts on the fatty acids and/or cholesterol metabolisms in the brain. Cholesterol 243-254 peroxisome proliferator activator receptor delta Mus musculus 89-97 15939051-2 2005 Administration of synthetic PPARdelta agonists to obese rhesus monkeys elevates serum high-density lipoprotein (HDL) cholesterol as a result of increased reverse cholesterol transport whilst in vitro studies have suggested a role for PPARdelta in lipid uptake into macrophages. Cholesterol 117-128 peroxisome proliferator activator receptor delta Mus musculus 28-37 15939051-2 2005 Administration of synthetic PPARdelta agonists to obese rhesus monkeys elevates serum high-density lipoprotein (HDL) cholesterol as a result of increased reverse cholesterol transport whilst in vitro studies have suggested a role for PPARdelta in lipid uptake into macrophages. Cholesterol 162-173 peroxisome proliferator activator receptor delta Mus musculus 28-37 15604518-0 2005 Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. Cholesterol 8-19 peroxisome proliferator activator receptor delta Mus musculus 36-45 15604518-2 2005 Activation of PPARdelta may have antiatherogenic effects through the increase of plasma HDL, theoretically promoting reverse cholesterol transport from peripheral tissues toward the liver for removal via bile and feces. Cholesterol 125-136 peroxisome proliferator activator receptor delta Mus musculus 14-23 15001574-3 2004 PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids. Cholesterol 308-319 peroxisome proliferator activator receptor delta Mus musculus 0-8 10818235-3 2000 Here we show that treatment of insulin resistant db/db mice with the PPARdelta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. Cholesterol 181-192 peroxisome proliferator activator receptor delta Mus musculus 69-78 10818235-7 2000 These data suggest both that PPARdelta is involved in the regulation of cholesterol metabolism in db/db mice and that PPARdelta ligands could potentially have therapeutic value. Cholesterol 72-83 peroxisome proliferator activator receptor delta Mus musculus 29-38